

Original Research Article

Role of Fecal Calprotectin in Detection of Gastrointestinal Injury in Preterm Infants

Osama A. El-Fiky¹, Neveen T. Abed¹, Nehad T. Bishr¹, Shuzan A. Mohammed^{2*}¹Pediatrics Department, Faculty of Medicine, Benha University, Farid Nada Street, Benha 13511, Qaliubiya Governorate, Egypt.² Department of Medical Biochemistry, Faculty of Medicine, Benha University, Farid Nada Street, Benha 13511, Qaliubiya Governorate, Egypt.

*Corresponding author

Shuzan A. Mohammed

Email: shuzan.ali@fmed.bu.edu.eg

Abstract: Necrotizing enterocolitis (NEC) is a devastating bowel disease, preterm face. This study aimed to explore the role of fecal calprotectin (FCP) as a noninvasive marker of gastrointestinal (GI) injury in preterm infants to detect its usefulness in diagnosis and prediction of NEC severity. On 38 preterm infants a prospective cohort study was carried out. Eighteen preterm infants showed feeding intolerance (FI) and 20 showed feeding tolerances (controls). The preterm infants were recruited from the neonatal intensive care unit, Benha University Hospital, from June 2014 to Dec 2015. FCP was estimated by ELISA in Baseline and follow-up samples. Hematologic parameters were also estimated. FCP showed non-significant baseline difference but was significantly increased at the 2nd sample in FI compared to controls. Within the FI group, highly significantly increased FCP was found in follow-up samples (2nd and 3rd) compared to the 1st. FCP (2nd and 3rd) significantly elevated with increased severity of enteropathy grades. FCP (3rd) was highly significantly increased in died compared to survived infants. Significant positive correlations between FCP (2nd and 3rd) with both Bell's staging and CRP were found. Significant negative correlations between FCP (2nd) and platelets, pH, pCO₂ and HCO₃⁻ but significant negative correlations between FCP (3rd) and hemoglobin, hematocrit, platelets, pH, HCO₃⁻ and sodium were found. FCP cutoff levels; 120.5µg/g for NEC occurrence, 128.7µg/g for definite NEC and 215.5µg/g for advanced NEC were determined. To conclude, our study showed increased FCP in preterm with GI inflammation (particularly NEC) compared to controls, with a significant positive correlation with NEC severity. FCP could distinguish NEC from more benign FI. Serial measurements might be a useful non-invasive tool for prediction of NEC severity and prognosis.

Keywords: fecal calprotectin, feeding intolerance, necrotizing enterocolitis, noninvasive tool, ELISA

INTRODUCTION

Necrotizing enterocolitis (NEC) is one of the most common and serious acquired bowel diseases a premature newborn can face [1]. NEC diagnosis currently relies on modified Bell's staging criteria which may overlap with other clinical conditions. This diagnostic uncertainty can result in improper medical management [2].

Identification of a reliable marker, able to predict NEC onset, unambiguously diagnose, predict severity and prognosis, and determine resolution is important. Many serological markers, evaluated for diagnosing NEC, identify systemic inflammation and lack sufficient specificity [3]. A noninvasive sampling is preferred especially in preterm infants to avoid pain

and anemia caused by frequent blood sampling [4].

Calprotectin is a 24kDa heterodimer of calcium binding proteins S100A8 and S100A9 [5]. Calprotectin, released by leukocytes at the site of inflammation, is easily measured in feces being stable for one week. Increased fecal calprotectin (FCP) levels are found in several inflammatory conditions, mainly inflammatory bowel diseases [6]. This study aimed to explore the role of FCP as a noninvasive marker of gastrointestinal (GI) injury in preterm infants to detect its usefulness in diagnosis and prediction of NEC severity.

METHODS

This prospective cohort study was carried on 38 preterm infants, recruited from the neonatal intensive care unit (NICU), Benha University Hospital, from June 2014 to Dec 2015. Approval of the study by the Ethical Scientific Committee of the Faculty of Medicine, Benha University was obtained, with informed consents obtained from all parents of included newborns.

Study design

Preterm infants (≤ 34 weeks) were followed for early signs of GI injury manifested by feeding intolerance (FI). GI congenital anomalies, newborns failed to pass stool, died before sampling or due to other complications were excluded. Infants were divided accordingly into 2 groups; Group I: 18 infants with FI: gastric residual volume $>50\%$ of prior feed, abdominal girth increase $>1.5\text{cm}$ accompanied with other FI symptoms, emesis $>3\text{times}/24\text{hours}$ with bilious, blood stain, blood or guaiac-positive stools [7]. Group II: 20 infants achieved *full gavage feedings* with no FI; they achieved appropriate weight gain ($\sim 15\text{g}/\text{kg}/\text{day}$) without parenteral nutrition [8]. This occurred on receiving $120\text{kcal}/\text{kg}/\text{day}$ ($150\text{ml}/\text{kg}/\text{day}$).

All preterm infants were subjected to full history taking and thorough clinical examination stressing on gestational age assessment using expanded Ballard score [9], anthropometric measures, correlation with centiles, vital data, general examination (conscious state, neonatal reflexes, color and perfusion) and systemic examination (especially abdominal assessing intestinal sounds and GI injury signs). GI injury severity was determined by modified Bell's staging criteria for NEC. Plain x-ray abdomen was done for group I.

Sampling and Laboratory investigations:

Blood samples were taken as a part of routine assessment in the NICU; 1ml venous blood on ethylene-diamine tetra-acetic acid for complete blood count (CBC), 1ml venous blood centrifuged to separate serum for C-reactive protein (CRP) and 1ml heparinized capillary blood for arterial blood gases (ABG) and electrolyte measurement. Fecal samples were collected before the start of feeding for baseline FCP (1st sample). Feeding tolerance was assessed daily starting on the first day that feedings were attempted. On FI symptom appearance, a 2nd sample was obtained. FI infants were enrolled in group I. Preterm infants who achieved full gavage feeding with no FI were served as controls (group II). When feeding reached $\sim 120\text{kcal}/\text{kg}/\text{day}$ ($150\text{ml}/\text{kg}/\text{day}$) a 2nd sample was obtained from controls. In group I, a 3rd sample (follow up) was collected 3-5 days later to evaluate FCP correlation with the degree of GI injury and relation to prognosis.

FCP measurement by enzyme linked immunosorbent assay (ELISA)

Fecal samples were immediately stored at -20°C . FCP was measured by EDITM Quantitative Fecal Calprotectin ELISA kit (Epitope Diagnostics, Inc., CA, and USA). A stool specimen (50-100mg) was diluted twice (1:40 then 1:9 with fecal extraction buffer); 50 μl clear extract was used for the assay. Optical density was measured at 450nm by TECAN Infinite F50 ELIZA Reader (Singapore). A point-to-point fitting standard curve was generated with result calculation using Magellan Tracker software (Tecan Trading AG, Switzerland).

STATISTICAL ANALYSIS

The data were analyzed using SPSS version 16. Quantitative data were expressed as Mean \pm SD and qualitative data were expressed as percentages. Student's *t*-test was used to compare mean of quantitative data among two groups, paired *t* test to compare mean of variables of quantitative data in the same group. ANOVA test (F value) was used to compare mean of quantitative data among more than 2 groups of with post-hoc test (LSD) for multiple comparisons. Z test was used to compare proportion between two groups of qualitative data. Inter-group comparison of categorical data was performed using chi square test (X^2), fisher exact test (FET). Correlation coefficient (*r*) was used to find relationships between variables. Cutoff values were determined using the receiver operating characteristics (ROC) curve analysis. $p < 0.05$ was significant and $p < 0.01$ was highly significant.

RESULTS

In the current study, no statistically significant differences could be detected between the studied groups as regard characteristic data and feeding criteria [Table 1].

At the 1st (baseline) sample; there was non-significant FCP and other laboratory investigations between the studied groups. However, at the 2nd sample; there were highly significant increases in FCP, leucocytes and CRP ($p=0.001$ for all) but significant decreases in platelets ($p=0.001$), $p\text{CO}_2$ ($p=0.001$) and HCO_3^- ($p=0.001$) and pH ($p=0.48$) [Table 2].

In group I, FCP was highly significantly increased in serial stool samples (2nd and 3rd) (154.49 ± 59.27 and 166.36 ± 53.95 , respectively) compared to the 1st sample (40.98 ± 19.59) ($p=0.001$). There was a highly significant progressive increased CRP in serial samples ($p=0.008$). However, there were highly significant decreases in hemoglobin ($p=0.001$), hematocrit ($p=0.001$), platelets ($p=0.001$) and $p\text{CO}_2$ ($p=0.006$) in the 2nd and 3rd samples compared to 1st. Also, there was a highly significant decrease in

leucocytes ($p=0.001$), pH ($p=0.002$), HCO_3^- ($p=0.001$) and sodium ($p=0.001$) in the 3rd sample compared to 1st and 2nd [Table 3].

There were statistical significant differences in FCP at 2nd and 3rd samples within different grades of enteropathy among group I. At the 2nd sample, infants were distributed according to Bell's staging; 22.2% (stage 0), 22.2% (stage Ia), 16.7% (stage Ib), 22.2% (stage IIa) and 16.7% (stage IIb) with significantly

increased FCP levels as the severity increased (102 ± 9.91 , 137.51 ± 66.8 , 148.97 ± 20.26 , 165.9 ± 49.87 and 237.4 ± 46.67 , respectively, $p=0.023$). At the 3rd sample, infants were also distributed according to Bell's staging; 50% (stage 0), 16.7% (stage IIb), 22.2% (stage IIIa) and 1.1% (stage IIIb) with significantly increased FCP levels as the severity increased (38.67 ± 18.12 , 224.63 ± 66.32 , 321.83 ± 109.88 and 406.45 ± 42.78 respectively, $p=0.001$) [Table 4].

Table 1: Characteristic data and feeding criteria of the studied groups

Variables	Group I (n.=18)	Group II (n.=20)	Test	p
	n.(%) or Mean±SD			
Sex (Male/Female)	10(55.6%)/8(44.4%)	9(45%)/11(55%)	$\chi^2=0.422$	0.516
Mode of delivery (CS/NVD)	9(50%)/9(50%)	9(45%)/11(55%)	$\chi^2=0.095$	0.758
Gestational age (weeks)	31.56±1.10	31.55±1.64	0.012	0.99
Birth weight (grams)	1426.1±148.0	1462.5±206.6	0.618	0.541
Maternal diseases				
PROM/PE/PE&PROM	2(11.1%)/1(5.6%)/1(5.6%)	3 (15%)/2(10%)/0(0%)	FET=1.56	1.0
Neonatal diseases				
Respiratory distress syndrome	13(72.2%)	11(55%)	Z=0.41	0.341
Early onset sepsis	0(0%)	4(20%)	-	-
Late onset sepsis	12(66.6%)	9(45%)	Z=0.456	0.324
Small for gestational age	3(16.7%)	4(20%)	Z=0.382	0.351
Patent ductus arteriosus	2(11.1%)	3(15%)	Z=0.456	0.324
Intra-ventricular hemorrhage	1(5.6%)	0(0%)	-	-
Lung collapse	1(5.6%)	0(0%)	-	-
Air leak	1(5.6%)	0(0%)	-	-
Feeding criteria				
Start of feeding (days)	4.28±2.02	4.75±2.4	0.651	0.519
Breast feeding/Formula/Mixed	6 (33.3%)/5(27.8%)/7(38.9%)	10 (50%)/6(30%)/4(20%)	FET=1.8	0.427
Number of feeds/day	7.22±2.07	8.40±2.87	1.43	0.16
Initial rate (ml/kg/d)	17.66±8.78	21.47±9.33	1.29	0.205
Rate of increment (ml/kg/d)	13.47±6.49	17.12±5.31	1.9	0.065

CS: caesarian section, NVD: normal vaginal delivery, PROM: premature rupture of membranes, PE: preeclampsia

Table 2: Laboratory parameters of the studied groups (1st and 2nd samples)

Variables	1 st sample				2 nd sample			
	Group I (n.=18)	Group II (n.=20)	St t test	p	Group I (n.=18)	Group II (n.=20)	St t test	p
	Mean±SD				Mean±SD			
FCP ($\mu\text{g/g}$)	40.98±19.59	42.31±23.22	0.189	0.851	154.49±59.27	35.90±15.72	8.63	0.001**
Hemoglobin (gm/dl)	15.32±1.02	15.31±1.45	0.004	0.997	13.17±1.93	13.1±1.51	0.119	0.906
Hematocrit (%)	48.47±3.61	47.58±4.60	0.659	0.514	39.91±5.99	39.88±4.57	0.018	0.986
Leucocytes ($\times 10^9/\text{L}$)	11.58±3.63	11.33±3.98	0.204	0.938	12.47±3.43	8.46±1.39	4.82	0.001**
Platelets ($\times 10^9/\text{L}$)	233±32.33	228±56.81	0.348	0.73	164±40.40	272±44.647	7.84	0.001**
CRP (mg/L)	7.39±6.31	11.55±20.16	0.838	0.407	26.06±24.81	4.5±0.51	3.89	0.001**
pH	7.38±0.027	7.37±0.04	0.784	0.438	7.36±0.05	7.39±0.02	2.05	0.048*
pCO ₂ (mmHg)	43.49±3.79	44.83±4.55	0.976	0.336	37.51±4.5	41.68±1.28	3.98	0.001**
HCO ₃ ⁻ (mmol/L)	24.26±1.27	24.61±1.18	0.893	0.378	22.44±1.74	24.39±0.86	4.45	0.001**
Sodium (mmol/L)	140.11±3.32	139.85±3.69	0.228	0.821	139.5±4.64	140.1±2.1	0.522	0.605
Potassium (mmol/L)	4.30±0.55	4.29±0.63	0.023	0.982	4.3±0.61	4.37±0.44	0.42	0.677

FCP: fecal calprotectin, CRP: C-reactive protein, pH: power of hydrogen, pCO₂: partial pressure of carbon dioxide, HCO₃⁻: bicarbonate, *: significant, **: high significant

Table 3: Laboratory parameters in serial samples among group I

Variables	Group I (n.=18)			ANOVA	p
	1 st sample	2 nd sample	3 rd sample		
	(Mean±SD)				
FCP (µg/g)	40.98±19.59	154.49±59.27 ^a	166.36±53.95 ^a	9.74	0.001 ^{**}
Hemoglobin (gm/dl)	15.32±1.02	13.17±1.93 ^a	11.99±2.66 ^a	12.95	0.001 ^{**}
Hematocrit (%)	48.47±3.61	39.91±5.99 ^a	37.33±9.45 ^a	13.27	0.001 ^{**}
Leucocytes (x10 ⁹ /L)	11.58±3.63	12.47±3.43	7.68±4.49 ^{a,b}	7.8	0.001 ^{**}
Platelets (x10 ⁹ /L)	233±32.328	164±40.401 ^a	137±10.419 ^a	9.78	0.001 ^{**}
CRP (mg/L)	7.39±6.31	26.06±24.8 ^a	50.22±63.54 ^{a,b}	5.31	0.008 ^{**}
pH	7.38±0.027	7.36±0.05	7.28±0.14 ^{a,b}	7.27	0.002 ^{**}
pCO ₂ (mmHg)	43.49±3.79	37.51±4.5 ^a	37.98±8.38 ^a	5.7	0.006 ^{**}
HCO ₃ ⁻ (mmol/L)	24.26±1.27	22.44±1.74	18.98±5.97 ^{a,b}	9.61	0.001 ^{**}
Sodium (mmol/L)	140.11±3.32	139.5±4.64	132.1±10.4 ^{a,b}	7.53	0.001 ^{**}
Potassium (mmol/L)	4.3±0.55	4.3±0.61	4.47±0.87	1.1	0.09

FCP: fecal calprotectin, CRP: C-reactive protein, pH: power of hydrogen, pCO₂: partial pressure of carbon dioxide, HCO₃⁻: bicarbonate, ^a: significant compared to 1st sample, ^b: significant compared to 2nd sample, ^{**}: high significant

Table 4: FCP among group I in different grades of enteropathy (2nd and 3rd samples)

Group I (n.=18)	Bell's staging	n.(%)	FCP (µg/g)	ANOVA	p
2 nd sample	0	4(22.2%)	102±9.91	4.13	0.023*
	Ia	4(22.2%)	137.51±66.8		
	Ib	3(16.7%)	148.97±20.26		
	IIa	4(22.2%)	165.9±49.87		
	IIb	3(16.7%)	237.4±46.67		
3 rd sample	0	9(50.0%)	38.67±18.12	34.71	<0.001 ^{**}
	IIb	3(16.7%)	224.63±66.32		
	IIIa	4(22.2%)	321.83±109.88		
	IIIb	2(11.1%)	406.45±42.78		

*: significant, **: high significant

There was a high significant increase in the follow up FCP (3rd sample) in the nine died group I infants (308.23±104.79) compared to the nine survived

infants (38.67±18.12) (Student t test=7.60 and p=0.001) [Figure 1].




Fig 1: Follow up FCP (3rd sample) as regard survival among group I

Figure 1 legend: A high significant increase was detected in the follow up FCP (3rd sample) in died

compared to survived infants among group I (Student t test=7.60 and p=0.001).

Statistically significant positive correlations

between FCP (2nd and 3rd sample) with both Bell's

staging and CRP were found among group I. However, there were statistically significant negative correlations between FCP 2nd sample and platelets, pH, pCO₂ and HCO₃⁻. Moreover, statistically significant negative correlations between FCP (3rd sample) and hemoglobin, hematocrit, platelets, pH, HCO₃⁻ and sodium were found [Table 5].

determined; 120.5µg/g for occurrence of NEC with 92.9% sensitivity, 100% specificity and area under curve (AUC) 0.929, 128.7µg/g for occurrence of definite NEC (Bell's stage ≥IIa) with 100% sensitivity, 63.6% specificity and AUC 0.844 and 215.5µg/g for occurrence of advanced NEC (Bell's stage ≥IIIa) with 100% sensitivity, 91.7% specificity and AUC 0.972. [Table 6, Figure 2]

Three cutoff levels of FCP (2nd sample) were

Table 5: Correlation between FCP (2nd and 3rd samples), Bell's staging and other laboratory parameters among group I

Group I (n.=18)	FCP (µg/g)			
	2 nd sample		3 rd sample	
	r	p	r	p
Bell's staging	0.705	0.001**	0.543	0.02*
Hemoglobin (gm/dl)	-0.402	0.098	-0.798	0.001**
Hematocrit (%)	-0.413	0.089	-0.800	0.001**
Leucocytes (x10 ⁹ /L)	0.099	0.695	-0.208	0.407
Platelets (x10 ⁹ /L)	-0.562	0.015*	-0.912	0.001**
CRP (mg/L)	0.684	0.001**	0.579	0.009**
pH	-0.48	0.044*	-0.883	0.001**
pCO ₂ (mmHg)	-0.704	0.001**	-0.335	0.174
HCO ₃ ⁻ (mmol/L)	-0.67	0.002**	-0.929	0.001**
Sodium (mmol/L)	-0.459	0.055	-0.875	0.001**
Potassium (mmol/L)	-0.202	0.423	0.337	0.170

FCP: fecal calprotectin, CRP: C-reactive protein, pH: power of hydrogen, pCO₂: partial pressure of carbon dioxide, HCO₃⁻: bicarbonate, *: significant, **: high significant

Table 6: Cutoff value of FCP (2nd sample) for NEC according to Bell's stage

Group I (2 nd)	Cutoff (µg/g)	Specificity %	Sensitivity %	PPV %	NPV %	Accuracy	AUC	p
Bell's stage ≥Ia [†]	120.5	100	92.9	100	80.0	94.4	0.929	0.002**
Bell's stage ≥IIa [‡]	128.7	63.6	100	63.6	100	77.8	0.844	0.028*
Bell's stage ≥IIIa [¶]	215.5	91.7	100	85.7	100	94.4	0.972	0.001**

[†]: occurrence of NEC, [‡]: occurrence of definite NEC, [¶]: occurrence of advanced NEC, *: significant, **: high significant, PPV: positive predictive value, NPV: negative predictive value, AUC: area under curve




Fig 2: ROC curves of FCP (2nd sample)

Figure 2 legend: ROC curves of FCP (2nd sample); A: for occurrence of NEC (Bell's stage ≥Ia), B: for occurrence of definite NEC (Bell's stage ≥IIa) and C: for occurrence of advanced NEC (Bell's stage ≥IIIa).

DISCUSSION

The present study found no significant differences between baseline (1st sample) laboratory investigations among the studied groups. However, Cui and Li found significantly higher 1st FCP in preterm with FI than those with feeding tolerance [10]. In accordance with our study concerning other laboratory investigations, non-significant differences were previously reported between NEC and non-NEC as regard leucocytes, platelets, hemoglobin, hematocrit and ABG [11], initial CRP level [12] and pH [13].

As regard 2nd sample, FCP was significantly increased in group I compared to group II. In agreement, significantly higher 2nd FCP was found in preterm with FI compared to those with tolerance [10] and in NEC compared to controls [14], and to other diagnoses [4]. Moreover, significant elevated FCP was found at and 48 hours before NEC onset [15] and in suspected NEC infants who finally developed NEC (Bell's stage \geq II) [16, 17]. Our finding could be explained by the ejection of nuclear chromatin and bactericidal proteins in a structure known as neutrophil extracellular traps (NETs) to trap and kill microorganisms in a process termed NETosis [18]. FCP in excised NEC-affected bowel is one of the proteins released by neutrophils in association with NETs [17]. Also, NEC is an inflammatory intestinal disorder characterized by sequestration of neutrophils into the gut wall. Intestinal neutrophil influx followed by activation, results in degranulation and release of calprotectin [19]. In contrast, other studies showed that FCP did not differ between preterms with and without NEC. They explained this by the small sample size [20] or early disease stage of the studied newborns [21].

In our study, in group I (2nd sample), there were high significant increases in leucocytes and CRP but significant decreases in platelets, pH, pCO₂ and HCO₃⁻ compared to group II. Although significant, all values were within normal for this age group [22]. In agreement with our results, Hällström *et al.*; showed significant lower pH and platelets (platelets still within normal) with non-significant hematocrit, sodium and potassium at NEC onset compared to controls [23]. Moreover, significant increases in leucocytes and neutrophils in NEC were also obtained [24]. In other studies, slightly increased immature to total neutrophils ratio [17] and higher CRP with no significant differences in hemoglobin and hematocrit were also reported [11]. In contrast, previous studies reported non-significant platelet count and CRP level but significant lower leucocytes [19], significantly decreased hemoglobin, [24] pH and ABG levels in NEC versus other diagnoses [11].

In our study, as regard serial fecal samples in group I, there was highly significant increased FCP at

2nd and 3rd samples compared to 1st sample. In accordance, Aydemir *et al.*; and MacQueen *et al.*; reported significantly higher FCP in the follow-up sample of NEC compared to controls in 1st and 2nd samples. In stage III NEC, FCP increased even more in 2nd sample, although not significant. In contrast, in stage II NEC, FCP decreased significantly in 2nd sample [13, 17].

As regard laboratory parameters of serial samples among group I, there were highly significant decreases in hemoglobin, hematocrit, platelets and pCO₂ in the 2nd and 3rd samples compared to the 1st. Also, there was a highly significant decrease in leucocytes, pH, HCO₃⁻ and sodium in 3rd sample compared to 1st and 2nd samples. Moreover, there was a highly significant progressive increased CRP in serial samples. Hällström *et al.* showed a drop in hemoglobin, hematocrit, platelets and pH with disease progression [23]. In addition, significantly dropped platelets from the day of diagnosis to the day prior operation [25] and higher CRP in NEC; at diagnosis and 3 days later [13] were also reported.

Our hematologic results could be explained by that: Thrombocytopenia is present in 50-95% of NEC infants. Advanced NEC develops thrombocytopenia 24-72 hours of disease onset that may be primarily due to increased platelet destruction. NEC patients may develop anemia due to multiple pathogenic mechanisms. In mucosal injury, thrombocytopenia, and coagulation disturbances, occult and obvious blood loss are common. Hemolysis by thrombotic microangiopathy can further worsen anemia. Finally, NEC infants may be at increased risk of inflammatory suppression of erythropoiesis. Neutrophilia comprise an appropriate inflammatory response in NEC, however, neutropenia may be associated with adverse outcome in severe NEC [26].

The current study showed increased FCP with the increased disease severity and statistically significant positive correlations between FCP (2nd and 3rd samples) and degree of enteropathy (Bell's staging) among NEC infants. In agreement with the present study, Aydemir *et al.*; reported a significant positive correlation between FCP and NEC severity [27], moreover, Albanna *et al.*; observed that FCP was maximum in Bell's stage IIIb [24].

In contrast to our results, Däbritz *et al.*; found that FCP did not differ with disease severity [15]. Moreover, Zoppelli *et al.*; observed elevated FCP 12-48 hours before clinical signs in moderate NEC, however, FCP was low in fulminant NEC. They explained their results by the impaired recruitment of granulocytes in the GI lumen of VLBW infants which could make them at risk for aberrant postnatal microbial colonization and

subsequent NEC [12].

We studied the follow-up FCP (3rd sample) as regard survival among patients. Half the patients died and the other half improved. FCP (3rd sample) was highly significantly increased in died cases compared to the survived. Our result agreed with Albanna *et al.*; who reported that 33.3% of their patients improved and 66.7% died with highly significantly increased FCP in died patients [24]. On the other hand, FCP did not significantly differ in fatal compared to medical NEC [25].

As regard the correlations, there was a statistically significant negative correlation between FCP (2nd sample) and platelets, pH, pCO₂ and HCO₃⁻ and between FCP (3rd sample) and hemoglobin, hematocrit, platelets, pH, HCO₃⁻ and sodium. However, there was a statistically significant positive correlation between FCP and CRP in 2nd and 3rd samples. Our results agreed with Aydemir *et al.*; who showed a significant positive correlation between FCP and CRP at diagnosis and 3 days later in NEC [13] but no correlation between FCP and CRP in non-NEC suggesting that systemic infection does not affect FCP level in absence of severe abdominal disease [20]. In a previous study, significantly decreased platelets with increasing NEC severity were found [25]. In addition, severe NEC (with bowel perforation) was more likely to exhibit thrombocytopenia, significant increased CRP, and relatively low pH compared to those without perforation [28]. Moreover, it was concluded that hyponatremia, severe acidosis and thrombocytopenia might be indicators of clinical worsening in NEC [29]. All of the above findings together with Maheshwari *et al.*; study on immunologic and hematological abnormalities in NEC may support our findings regarding correlation between FCP and laboratory parameters [26].

To distinguish NEC from more benign FI forms and predict disease progression, different cutoff levels were estimated; 120.5µg/g for occurrence of NEC (92.9% sensitivity, 100% specificity and AUC 0.929), 128.7µg/g for definite NEC (100% sensitivity, 63.6% specificity and AUC 0.844) and 215.5µg/g for advanced NEC (100% sensitivity, 91.7% specificity and AUC 0.972).

Zoppelli *et al.*; detected a FCP cutoff 110µg/g showing 89% sensitivity and 87% specificity to detect moderate NEC 24 hours before clinical symptoms, whereas a cutoff 210µg/g with 89% sensitivity and 84% specificity was reported for definite NEC [12]. Thuijls *et al.*; reported that a cutoff 286.2µg/g with 93% sensitivity and 86% specificity discriminated NEC from suspected NEC with other final diagnoses [19]. Josefsson *et al.*; suggested a cutoff 2000µg/g for

identifying severe intestinal inflammation [20].

CONCLUSIONS

Our results showed a substantial difference between FCP levels in preterm infants with features of GI inflammation (particularly NEC) compared to controls, with a significant positive correlation with NEC severity. FCP level could help distinguish NEC from more benign forms of FI. Serial FCP measurements might be a useful non-invasive tool for prediction of NEC severity and prognosis and help planning the length of enteral fasting, total parenteral nutrition and antibiotics.

Acknowledgment

Authors would like to thank the parents of preterm infants included in the study. Deep thanks to the Molecular Biology Unit, Faculty of Medicine, Benha University for technical support.

Funding: This research did not receive any fund.

No conflict of interest

Ethical approval: The study was approved by the Ethical Scientific Committee of the Faculty of Medicine, Benha University.

REFERENCES

1. Sharma R, Hudak ML. A clinical perspective of necrotizing enterocolitis: past, present, and future. *Clinics in perinatology*. 2013 Mar 31; 40(1):27-51.
2. Nantais-Smith L, Kadrofske M. Noninvasive biomarkers of necrotizing enterocolitis. *The Journal of perinatal & neonatal nursing*. 2015 Jan 1; 29(1):69-80.
3. Evennett N, Alexander N, Petrov M, Pierro A, Eaton S. A systematic review of serologic tests in the diagnosis of necrotizing enterocolitis. *Journal of pediatric surgery*. 2009 Nov 30; 44(11):2192-201.
4. Reisinger KW, Van der Zee DC, Brouwers HA, Kramer BW, van Heurn LE, Buurman WA, Derikx JP. Noninvasive measurement of fecal calprotectin and serum amyloid A combined with intestinal fatty acid-binding protein in necrotizing enterocolitis. *Journal of pediatric surgery*. 2012 Sep 30; 47(9):1640-5.
5. Brophy MB, Nolan EM. Manganese and microbial pathogenesis: sequestration by the Mammalian immune system and utilization by microorganisms. *ACS chemical biology*. 2015 Jan 16; 10(3):641-51.
6. Rosso C, Caviglia GP, Pellicano R. Usefulness of fecal calprotectin determination in pediatric intestinal diseases. *Minerva pediatrica*. 2016 Dec; 68(6):478-86.

7. Moore TA, Wilson ME. Feeding intolerance: a concept analysis. *Advances in Neonatal Care*. 2011 Jun 1; 11(3):149-54.
8. Shulman RJ, Ou CN, Smith EO. Evaluation of potential factors predicting attainment of full gavage feedings in preterm infants. *Neonatology*. 2010 Jun 30; 99(1):38-44.
9. Ballard JL, Khoury JC, Wedig KL, Wang L, Eilers-Walsman BL, Lipp R. New Ballard Score expanded to include extremely premature infants. *The Journal of pediatrics*. 1991 Sep 1; 119(3):417-23.
10. Cui X, Li J. Fecal calprotectin levels in preterm infants during the early neonatal period. *Zhongguo dang dai er ke za zhi= Chinese journal of contemporary pediatrics*. 2012 Mar; 14(3):165-8.
11. Yoon JM, Park JY, Ko KO, Lim JW, Cheon EJ, Kim HJ. Fecal calprotectin concentration in neonatal necrotizing enterocolitis. *Korean J Pediatr* 2014; 57: 351-356.
12. Zoppelli L, Güttel C, Bittrich HJ, Andrée C, Wirth S, Jenke A. Fecal calprotectin concentrations in premature infants have a lower limit and show postnatal and gestational age dependence. *Neonatology*. 2012 May 16;102(1):68-74.
13. Aydemir O, Aydemir C, Sarikabadayi YU, Emre Canpolat F, Erdevi O, Biyikli Z, Dilmen U. Fecal calprotectin levels are increased in infants with necrotizing enterocolitis. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2012 Nov 1; 25(11):2237-41.
14. Moussa R, Khashana A, Kamel N, Elsharqawy SE. Fecal calprotectin levels in preterm infants with and without feeding intolerance. *Jornal de Pediatria (Versão em Português)*. 2016 Oct 31; 92(5):486-92.
15. Däbritz J, Jenke A, Wirth S, Foell D. Fecal phagocyte-specific S100A12 for diagnosing necrotizing enterocolitis. *The Journal of pediatrics*. 2012 Dec 31; 161(6):1059-64.
16. Bin-Nun A, Booms C, Sabag N, Mevorach R, Algur N, Hammerman C. Rapid fecal calprotectin (FC) analysis: point of care testing for diagnosing early necrotizing enterocolitis. *American journal of perinatology*. 2015 Mar; 32(04):337-42.
17. MacQueen BC, Christensen RD, Yost CC, Lambert DK, Baer VL, Sheffield MJ, Gordon PV, Cody MJ, Gerday E, Schlaberg R, Lowe J. Elevated fecal calprotectin levels during necrotizing enterocolitis are associated with activated neutrophils extruding neutrophil extracellular traps. *Journal of Perinatology*. 2016; 36(10):862-9.
18. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. *science*. 2004 Mar 5; 303(5663):1532-5.
19. Thuijls G, Derikx JP, van Wijck K, Zimmermann LJ, Degraeuwe PL, Mulder TL, Van der Zee DC, Brouwers HA, Verhoeven BH, van Heurn LE, Kramer BW. Non-invasive markers for early diagnosis and determination of the severity of necrotizing enterocolitis. *Annals of surgery*. 2010 Jun 1; 251(6):1174-80.
20. Josefsson S, Bunn SK, Domellöf M. Fecal calprotectin in very low birth weight infants. *Journal of pediatric gastroenterology and nutrition*. 2007 Apr 1; 44(4):407-13.
21. Selimoglu MA, Temel I, Yldrm Ç, Özyaln F, Aktas M, Karabiber H. The role of fecal calprotectin and lactoferrin in the diagnosis of necrotizing enterocolitis. *Pediatric Critical Care Medicine*. 2012 Jul 1; 13(4):452-4.
22. Andropoulos DB. *Pediatric normal laboratory values*. Gregory's Pediatric Anesthesia. 5th ed. Oxford, United Kingdom: Blackwell Publishing. 2012. p. 1300-14.
23. Hällström M, Koivisto AM, Janas M, Tammela O. Laboratory parameters predictive of developing necrotizing enterocolitis in infants born before 33 weeks of gestation. *Journal of pediatric surgery*. 2006 Apr 30; 41(4):792-8.
24. Albanna EA, Ahmed HS, Awad HA. Stool calprotectin in necrotizing enterocolitis. *Journal of clinical neonatology*. 2014 Jan 1; 3(1):16.
25. Reisinger KW, Kramer BW, Van der Zee DC, Brouwers HA, Buurman WA, van Heurn E, Derikx JP. Non-invasive serum amyloid A (SAA) measurement and plasma platelets for accurate prediction of surgical intervention in severe necrotizing enterocolitis (NEC). *PloS one*. 2014 Mar 6; 9(3):e90834.
26. Maheshwari A. Immunologic and hematological abnormalities in necrotizing enterocolitis. *Clinics in perinatology*. 2015 Sep 30; 42(3):567-85.
27. Aydemir G, Cekmez F, Asya Tanju I, Emre Canpolat F, Alparslan Gene F, Yildirim S, Tunc T, Umit Sarici S. Increased fecal calprotectin in preterm infants with necrotizing enterocolitis. *Clinical laboratory*. 2012 Jan 1; 58(7-8):841-44.
28. Yu L, Tian J, Zhao X, Cheng P, Chen X, Yu Y, Ding X, Zhu X, Xiao Z. Bowel perforation in premature infants with necrotizing enterocolitis: risk factors and outcomes. *Gastroenterology Research and Practice*. 2016; 2016:6134187..
29. Badowicz B. NEC--neonatal necrotising enterocolitis--methods of treatment and outcome: a comparative analysis of Scottish (Glasgow) and Polish (Western Pomerania) cases. In *Annales Academiae Medicae Stetinensis* 2000; 46: 137-49.